Table 1 Mean cognitive test scores at baseline (week 0) and after 12, 26, 52 and 78 weeks of cholinesterase inhibitor treatment for all patients and the sub-sample who had NARTIQ scores.
Test (week) | N All patients | Mean score | Standard deviation | N Patients with NARTIQ scores | Mean score | Standard deviation |
|---|---|---|---|---|---|---|
MMSE(0) | 626 | 19.3 | 5.8 | 346 | 20.7 | 4.9 |
HVLT(0) | 601 | 9.2 | 4.9 | 342 | 10.0 | 5.0 |
VF-Cat(0) | 604 | 7.8 | 4.3 | 344 | 8.7 | 4.4 |
VF-Lex(0) | 604 | 22.0 | 13.1 | 342 | 24.8 | 13.5 |
PAL(0) | 461 | 4.3 | 1.8 | 298 | 4.5 | 1.8 |
DMTS(0) | 447 | 11.1 | 3.1 | 290 | 11.5 | 2.8 |
MMSE(12) | 143 | 19.5 | 5.5 | 101 | 20.3 | 5.2 |
HVLT(12) | 84 | 9.7 | 5.6 | 67 | 10.2 | 5.7 |
VF-Cat(12) | 82 | 8.5 | 5.0 | 66 | 9.0 | 5.3 |
VF-Lex(12) | 82 | 24.3 | 14.9 | 66 | 25.7 | 15.2 |
PAL(12) | 70 | 4.2 | 1.7 | 59 | 4.1 | 1.7 |
DMTS(12) | 71 | 10.8 | 2.9 | 58 | 11.0 | 2.9 |
MMSE(26) | 259 | 19.0 | 5.6 | 162 | 19.7 | 5.5 |
HVLT(26) | 250 | 9.5 | 4.6 | 157 | 9.9 | 4.9 |
VF-Cat(26) | 248 | 7.6 | 4.2 | 158 | 8.1 | 4.5 |
VF-Lex(26) | 248 | 23.2 | 12.5 | 158 | 24.8 | 12.5 |
PAL(26) | 170 | 4.5 | 1.8 | 124 | 4.4 | 1.7 |
DMTS(26) | 183 | 11.1 | 3.1 | 127 | 11.2 | 3.0 |
MMSE(52) | 96 | 18.6 | 5.4 | 75 | 19.0 | 5.3 |
HVLT(52) | 87 | 9.2 | 5.7 | 69 | 9.3 | 5.8 |
VF-Cat(52) | 87 | 6.9 | 4.5 | 68 | 7.0 | 4.7 |
VF-Lex(52) | 87 | 23.5 | 13.9 | 68 | 25.0 | 14.0 |
PAL(52) | 76 | 4.4 | 1.6 | 62 | 4.3 | 1.6 |
DMTS(52) | 75 | 10.9 | 2.8 | 58 | 10.7 | 2.8 |
MMSE(78) | 43 | 19.2 | 5.5 | 33 | 19.6 | 5.7 |
HVLT(78) | 38 | 9.9 | 6.2 | 20 | 10.3 | 6.3 |
VF-Cat(78) | 39 | 7.6 | 4.7 | 31 | 7.9 | 5.0 |
VF-Lex(78) | 39 | 25.1 | 13.6 | 31 | 26.9 | 13.5 |
PAL(78) | 29 | 4.3 | 1.8 | 23 | 4.3 | 1.8 |
DMTS(78) | 33 | 10.6 | 3.4 | 25 | 10.7 | 3.4 |